Release date:2016-11-14  Release:


Associate Professor of Microbiology& Biological Pharmaceutics

School of Life Science & Technology

Phone: 86-25-83271483

Email: juancpu@126.com

Research Summary

Professor Zhang’s research focuses on the study of tumor targeted antibody therapeutics using phage display fully human antibody library and hybridoma technology.A number of monoclonal antibodies,bi-functional antibodies or fusion antibodies she designed exhibit promising anti-cancer effects either in cell therapy at clinical phases or pre-clinical phases.She recently published a paper entitled "VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer," in which the fusion antibody she designed recruits NK cell mediated immunotherapy.


2009   Ph.D., Microbiology& Biological Pharmaceutics, China Pharmaceutical University.Co- supervised Ph.D student, Imperial College, London. UK

2003    M.S., Microbiology& Biological PharmaceuticsChina Pharmaceutical University.

1997     B.S., Microbiological PharmacyChina Pharmaceutical University.

Academic Experience

2013 - 2014  Visiting Scholar, Geffen School of Medicine, University of California Los Angeles

2010 - present  Associate Professor of Microbiology& Biological PharmaceuticsChina Pharmaceutical University

2003 - 2009  Lecturer of  Molecular Biology

2001 - 2002  Teaching Assistant

Awards and Honors

2014  Young-and-Middle Aged Leading Academic professor of Jiangsu Province

2013  333-Project Talent of Jiangsu Province

2011  Sanofi-Aventis Young Scientist Prize in Biological Medicine, China Pharmaceutical Association

2010  Outstanding Young Teacher of Jiangsu Province  


*corresponding authors

  1. Ren XY,Xie W,Wang Y,Xu M,Liu F,Tang M,Li C,Wang M*, Zhang J*.VEGFR2 targeted fusion antibody improved NK cell mediated immunosurveillance against K562 cells" (DOI: 10.1007/s12026-016-8800-3)

  2. Lin MA,†, Kai GU1,†, Cheng-hai ZHANG1, Xue-tao CHEN1, Yi JIANG1, Karsten MELCHER3, Juan ZHANG,*, Min WANG*, H. Eric XU. Generation and characterization of a human nanobody against vascular endothelial growth factor receptor-2, Acta Pharmacologica Sinica .2016,37:1-7.

  3. Wei Xie#, Fang Liu#, Youfu Wang, Xueyan Ren, Tong Wang, Zhiguo Chen, Zhaoting Li, Min Wang*,Juan Zhang*. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer[J].Oncotarget,2016: 00-00.DOI10.18632/oncotarget.7501

  4. Tong Wang, Fumou Sun, Wei Xie, Mingying Tang, Hua He, Xuelian Jia, Xuemei Tian, Min Wang*, Juan Zhang*.A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma[J].Cancer Letters,372( 2016): 156-178.

  5. Zhuobin Xu, Zegen Wang, Xuelian Jia, Luxuan Wang, Zhiguo Chen, Shijing Wang, Min Wang*, Juan Zhang*,Min Wu*. MMGZ01, An anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.[J]. Cancer Letters, 2015;372(1).118-127.

  6. Zhiguo Chen, Wei Xie, Desmond Omane Acheampong, Menghuai Xu, Hua He, Mengqi Yang, Chenchen Li, Chen Luo, Min Wang*, and, Juan Zhang*. A Human IgG-like Bispecific Antibody Co-targeting Epidermal Growth Factor Receptor and the Vascular Endothelial Growth Factor Receptor 2 for Enhanced Antitumor Activity. Cancer biology& therapy, 2016 VOL. 0, NO. 0,-12 .PMID: 26671532.

  7. Mingying Tang, Desmond Omane Acheampong,Youfu Wang,Wei Xie, Min Wang*,Juan Zhang*.Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance. Immunol Res (2016) 64:754–764 .

  8. Xu, MenghuaiAcheampong, Desmond OmaneJin, HaizhenChen, ZhiguoXie, WeiWang, YoufuWang, YangWang, MinZhang, Juan*A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activityBiotechnology ProgressDOI: 10.1002/btpr.2231 2016

  9. Hua He, Xiaojie Tu, Juan Zhang*, Desmond Omane Acheampong, Li Ding, Zhaoxiong Ma, Xueyan Ren, Chen Luo, Zhiguo Chen, Tong Wang, Wei Xie, Min Wang* . A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging.Immunobiology,2015,220(12):1328-36.

  10. Zhao X, Acheampong DO, Wang Y, Tang M, Xie W, Chen Z, Wang M*, Zhang J*. Efficient in vitro refolding and characterization of Major Histocompatibility Complex class I-related chain molecules A (MICA) and Natural killer group 2 member D (NKG2D) expressed in E. coli . Protein Pept Lett. 2015;22(5):460-9.PMID:25925769.

  11. Wei Xie#,Daojuan Li# ,Juan Zhang*, Zhike Li,Desmond Omane Acheampong,Yuan He ,Youfu Wang,Zhiguo Chen,Min Wang*.Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2.Cancer Immunotherapy,2014,63(9):877-88.

  12. Xiaoniu Miao,Andong Li,Wei Chen,Haidi Qi, Zhen Qiu, Yubin Zhang,Juan Zhang*,Min Wang*.Optimization and Modification of Anti-rhTNF-α single chain variable fragment antibody: Effective In Vitro Affinity Maturation and Functional Expression of Chimeric Fab. Biomedicine & Pharmacotherap 2013, 67(5):437-44.

  13. Yaqiong Zhou, Haizhen Jin, Juan Zhang*, Zhiguo Chen, Ming Yue, Min Wang*. Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display-derived human scFv to EGFR. Biomedicine & Pharmacotherap 2013, 67(8):737-43.

  14. Li H, Cao W, Chen Z, Acheampong DO, Jin H, Li D, Zhang J*, Wang M*.The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.Biomedicine&pharmacotherapy,2013, 67(7):599-606.

  15. Wanlu Cao, Haixin Li,Juan Zhang*, Daojuan Li, Desmond Omane Acheampong , Zhiguo Chen,Min Wang*. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study. Protein Expression and Purification,2013,90(2):55-66.

  16. Wu Q, Zhang J*, Luo C, Zhang T, Wang T, Wang M*. Expression and Characterization of Recombinant Interleukin-21 Receptor and Its Targeting Single-Chain Variable Fragment Antibodies Selected from a Human Phage Display Library . DNA Cell Biol. 2012 Oct;31(10):1541-8. Jul 31.PMID:22849297.

  17. Zhang J*, Li H, Wang X, Qi H, Miao X, Zhang T, Chen G, Wang M*. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.Biotech Progr, 2012;28(4):981-989.

  18. Juan Zhang, Haixin Li,Wei Chen,Peng Cao,Min Wang*. Preparation of Extracellular Domain 3 of Human Vascular Endothelial Growth Factor (VEGF) Receptor-2 and the Monitoring of Its Real-time Binding to VEGF by Biosensors. Biotechnol Progr, 2009,251703-1708.

  19. Juan Zhang, Min Wang, Jae Min Cha,Athanasios Mantalaris. The Incorporation of 70s Bioactive Glass to the Osteogenic Differentiation of Murine Embryonic Stem Cells in 3-D Bioreactors. J Tissue Eng Regen Med 2009; 3: 63–71.

  20. Wei Chen#, Juan Zhang#, Tao Zhang, Haixin Li, Wenyi Wang, Zhinan Xia, Min Wang*. Improved Isolation of Anti-rhTNF-a scFvs from Phage Display Library by Bioinformatics . Mol Biotechnol.2009, 43:20–28.